DEBRICHEM®
The 60-Second Chemical Debridement
- Removes biofilm and devitalised tissue
- Easy to use in any medical setting
- Frees up hospital capacity & resources
Accelerate healing, reclaim time, transform outcomes.
Single 60-second treatment to retake control of wound infection.
Get a Grip on Wound Infections
15+ peer-reviewed publications from laboratory mechanism to patient outcomes and system-level impact.
See the Evidence in Practice
Request a free demonstration. We walk you through application, mechanism, and expected outcomes with your clinical team.
What is DEBRICHEM®?
What It Is
A non-surgical chemical debridement solution for wound bed preparation. Supplied in a single-use vial and applied by healthcare professionals in clinic, ward, community, or theatre settings.
What It Does
A controlled 60-second application that desiccates and removes slough, devitalised tissue, and disrupts biofilm. Leaves a clean, dry, dressing-ready wound bed that supports onward healing decisions.
What's Next
Enables immediate progression to NPWT, grafting or closure, or standard dressings as clinically indicated. Supports efficient workflows by preparing the wound for the next step, without delay.
How It Works: 3-Step Clinical Workflow
Prepare
Cleanse and dry the wound surface. Manage pain with local analgesia as clinically required.
Apply - 60 Seconds
Apply DEBRICHEM® evenly across the wound bed. Maintain a controlled contact time of 60 seconds. Single application per patient session.
Rinse & Proceed
Rinse thoroughly with saline to stop the reaction. Gently remove loosened debris with a dry gauze. Proceed directly to NPWT, grafting, or standard dressings.
DEBRICHEM® Case Studies
Same chemistry. Same mechanism. Across all wound types.
TESTIMONIALS
LISTEN TO WHAT DEBRICHEM® USERS SAY
"I've been trying DEBRICHEM® on patients with diabetic foot emergencies (foot attack) with necrotizing fasciitis and who are also septic.
What I have observed so far is the rapid control of the local infection and the early appearance of healthy granulation tissue."
The presence of infection and biofilm is a major obstacle to healing, slowing or preventing wound healing, requiring extensive debridement of the affected tissue with additional problems such as aggression of healthy tissue, pain, repeated procedures and added costs of operating theatre, diagnostic tests, local treatment and other procedures.
The availability of DEBRICHEM® has allowed us to quickly and cost-effectively address the removal of biofilm and infected tissue, facilitating optimal wound bed preparation for early application of other advanced therapies such as grafts or advanced healing products that reduce the time to closure of complex wounds.
It has also allowed us to rationalise the use of antibiotics and avoid the risk of antibiotic resistance and other problems related to antibiotic treatments.
"Some infected wounds are difficult to debride without taking the patient to the OR.
Where there is exuberant lumpy bumpy irregular granulation tissue for example.
In my experience one application of DEBRICHEM® will completely solve that problem.
By the next week you will be left with a perfectly healthy wound bed."
"Biofilm is an enemy to wound healing. Imagine working on a Monday morning in a clinic setting where workload is way out of hand, and you have a patient that needs for a debridement but you are not free to do so, patient has high risk of bleeding and cannot tolerate pain that well, but you still need to remove the biofilm and bioburden.
What's the quickest and fastest way without compromising the good tissues? DEBRICHEM® by DEBX Medical is the answer. With a few drops from 'heaven; your biofilm eradication works like magic. Even fairy godmother won't be able to do this trick that fast. Surely the result will stun you.
Furthermore, it reduces your time to attend to patient, reduces the cost of patient's visit, no hospitalization, no bleeding and definitely, a fast desirable outcome."
Start Your First Patient
Request a free clinical demonstration. We guide you through the first application.
UK Markov Model: Cost-Effectiveness Data
Peer-reviewed UK health economic analysis comparing DEBRICHEM® + standard care vs. standard care alone over 12 months.
Source: Guest et al. 2022, Journal of Wound Care
Build Your Business Case
Request a demonstration for your service. We provide all procurement documentation, cost models, and governance templates.
How to Order
Select your setting to see relevant access information, action steps, and downloadable resources.
NHS Supply Chain eDirect
What you need:
- NHS SC account access
- Clinical sponsor (TVN, Podiatry, or Surgical service lead)
- Procurement contact to enable category
Action steps:
- Nominate clinical sponsor - Identify TVN, Podiatry lead, or Surgical service champion
- Submit business case - Use provided template with evidence pack, KPIs, and safety governance
- Procurement enables category - Request "Chemical Wound Debridement Acidic Gel" on eDirect (Supplier: Creed Health Ltd). Procurement retrieves NPC for your trust.
- Raise PO through NHS SC - Standard ordering via eDirect platform
- Receive delivery - Typically 3-5 working days
- Evaluation period - 4-8 week evaluation with agreed KPIs
Expected timeline:
2-4 weeks from business case submission to NHS SC enablement. No tender required.
Drug Tariff FP10/EPS
What to prescribe:
Action steps:
- Prescribe via FP10 or EPS - Use codes above. Write "Debrichem gel 3ml vial" on prescription.
- Pharmacy dispenses - Community pharmacy orders via wholesaler. Drug Tariff Part IX ensures reimbursement.
- Patient receives - Typical availability: next working day to 3 days.
Private Direct Order
Creed Medical
Unit 2, Hamilton Court,
Oakham Business Park Mansfield,
Notts, NG18 5FB, UK
Phone: +44 (0) 1623 391578
Email: [email protected]
What you need:
- Company details (clinic name, address, contact)
- Credit check or proforma payment
Action steps:
- Contact UK distributor - Request account setup
- Complete credit application - Standard credit check or proforma invoice option
- Place order - Submit order form or purchase order
- Receive onboarding pack - All governance documents, SOP, competency checklist in one email
- Delivery - Standard shipping to clinic address
Friction eliminated: Complete onboarding package included with first order.
Everything You Need to Start Prescribing
Six documents. Every field pre-populated with prescribing codes, published evidence, and cost data. Open, complete the highlighted fields, submit.
Questions & Answers
Common clinical questions, clearly addressed.
According to Shabes et al. (2025), pain during DEBRICHEM® use was comparable to sharp debridement when appropriate anaesthesia was applied.
Access the full scientific library: debx-medical.com/scientific-papers
By rapidly removing devitalised tissue and biofilm, DEBRICHEM® converts the wound bed into a cleaner, more stable surface, allowing NPWT to be applied immediately and work as intended.
According to Hermans (2023), DEBRICHEM® was used to stabilise chronic, non-healing wounds, enabling progression to NPWT and subsequent healing.
According to Güven et al. (2024), improvement in infection severity scores supported antibiotic stewardship decisions in DFU cases.
Approval discussions commonly focus on: clinical rationale and evidence base, safety profile and controlled application protocol, and fit within existing wound care pathways.
DEBx Medical can provide supporting documentation and clinical evidence to facilitate internal review and approval processes.
Implementation typically involves: brief staff training on preparation, 60-second application, and rinsing; alignment with local pain management and infection control protocols; and clear positioning within debridement and wound bed preparation pathways.
Most centres implement DEBRICHEM® as an early wound bed preparation step, allowing immediate progression to NPWT, grafting or closure, or standard dressings as clinically indicated.
Copy-Paste Toolkit
Ready-made emails, procurement forms, and evaluation templates. Copy, personalise, send.
📧 Email: Approval Request to Product Evaluation Committee
I am submitting a business case for evaluation of DEBRICHEM® (chemical wound debridement acidic gel) to enhance our wound management pathways for complex chronic wounds.
Clinical Need: Our surgical teams routinely manage severe diabetic foot infections, dehisced incisions, stump breakdown, and pressure-related wounds that prolong length of stay and require repeat debridements.
Proposed Solution: DEBRICHEM® provides a 60-second chemical debridement that removes slough, disrupts biofilm, and stabilises the wound bed, enabling earlier NPWT, grafting, or discharge pathways.
Evidence Summary:
• UK cost-effectiveness: £4,067 savings per patient at 12 months (Guest et al. 2022)
• 75% higher healing probability vs. standard care
• 11-patient diabetic foot series: all achieved grafting, 6 limbs saved (Güven et al. 2024)
• 67-patient DFU series: 88.1% granulation (Snels et al. 2025)
Evaluation Plan: 4-8 week pilot with KPIs: slough reduction, granulation onset, infection resolution, antibiotic use, discharge readiness.
Access Route: NHS Supply Chain eDirect (Supplier: Creed Health Ltd). No tender required.
Complete business case, evidence dossier, and governance pack attached.
Please review and advise on committee presentation date.
Regards,
[Your Name, Title, Department]
📧 Email: Procurement Enablement Request (NHS SC)
Following Product Evaluation Committee approval, please enable the NHS Supply Chain category 'Chemical Wound Debridement - Acidic Gel' for our trust.
Supplier of record: Creed Health Ltd
Supply route: eDirect
Expected lead time: 3-5 working days
Clinical sponsor: [Name, Role, Department]
Please retrieve the NPC against our delivery code: [insert your trust code]
Evidence pack and business case reference attached.
Thank you,
[Your Name, Title]
📧 Email: Pharmacy Supply Request (Drug Tariff)
Please arrange supply of the following product for wound management:
Product: Debrichem gel 3ml vial
dm+d AMPP: 171448
SNOMED: 42488611000001102
GTIN: 08720299602915
NHS Price: £295.00 per vial (effective 01 Jan 2024)
Reimbursement: Drug Tariff Part IX
Typical availability via wholesaler: next working day to 3 days.
Coding block and usage guidance attached.
Thank you,
[Your Name, Title]
FAQ by Role
Questions organised by your professional role. Find your answers fast.
Can DEBRICHEM® be used at the bedside to reduce operating room time?
Yes. DEBRICHEM® can be applied at the bedside or in theatre-adjacent settings by trained clinicians. The single 60-second application enables effective wound bed preparation outside the operating room, supporting selective use of OR time for cases where surgical intervention is required.
What are the formal contraindications I should be aware of?
Refer to the IFU. Key exclusions include untreated ischaemia, dry full-thickness eschar unless removed, exposed bone or tendon, exposed grafts, face or anogenital areas, and known hypersensitivity.
Can DEBRICHEM® help reduce inpatient bed utilisation in post-surgical wounds?
DEBRICHEM® supports rapid wound bed preparation and early progression to definitive management. In post-surgical and hard-to-heal wounds, this can facilitate earlier step-down to outpatient care or community management, supporting discharge planning according to clinical judgement.
Is DEBRICHEM® easy to use in routine practice?
Yes. DEBRICHEM® is designed to be simple and intuitive, with a clear 60-second protocol. No extensive training is required, and the process fits easily into existing wound care workflows.
What training and educational support is available?
Clear written instructions, best practice documents and short usage videos are available. Your local distributor can also visit your service to provide a product demonstration and on-site educational session for clinical teams.
How do I get DEBRICHEM® approved for use in my service?
All required clinical, safety, and governance information is available to support local approval. Your distributor can support an on-site evaluation and guide you through each step of the approval process, working with your trust or service as needed.
What are the expected delivery lead times?
NHS Supply Chain eDirect: 3-5 working days. Drug Tariff FP10: 1-3 working days via community pharmacy. Private direct supply via Distributor: typically 3-7 days.
Is a formal tender required for NHS Supply Chain procurement?
No. DEBRICHEM® is available via NHS Supply Chain eDirect (Supplier: Creed Health Ltd) under "Chemical Wound Debridement - Acidic Gel".
What is the NHS price and reimbursement pathway?
NHS price: £295.00 per 3 ml vial (effective 01 Jan 2024). Community reimbursement via Drug Tariff Part IX. Hospital supply via standard NHS SC invoicing.
Is DEBRICHEM® listed on the Drug Tariff?
Yes. DEBRICHEM® is listed in Drug Tariff Part IX. NHS price: £295.00 per 3 ml vial (effective 01 Jan 2024).
How can DEBRICHEM® be supplied through pharmacy?
DEBRICHEM® can be supplied via NHS Supply Chain or through Drug Tariff Part IX for community prescribing. Hospital supply follows standard NHS Supply Chain ordering and invoicing processes.
Which product codes are required for prescribing and reimbursement?
dm+d AMPP: 171448 | SNOMED: 42488611000001102 | GTIN: 08720299602915 | Product name: Debrichem gel 3 ml vial
How does reimbursement operate in practice?
Community reimbursement is via Drug Tariff Part IX. Hospital use is managed through NHS Supply Chain billing. Standard pharmacy reimbursement processes apply.
DEBRICHEM® Amplifies Your Expertise
You bring clinical excellence. DEBRICHEM® adds the biofilm breakthrough. Together, you achieve outcomes previously out of reach.
You Are Already Excellent At
- Wound assessment and aetiology diagnosis
- Compression technique, NPWT application, dressing selection
- Patient education, follow-up care
- Managing complex comorbidities
DEBRICHEM® Adds
- Complete biofilm eradication in 60 seconds
- Therapy acceleration (your treatments work 30-80% better)
- Time efficiency (fewer repeat procedures)
- Clinical satisfaction (see outcomes you trained to achieve)
Together, You Achieve
- Patients healed who previously failed all therapies
- Time reclaimed for professional development
- Reputation enhanced as innovator and outcomes leader
- Burnout reduced through visible impact and professional pride
Take the Next Step
Request a clinical demonstration. All evidence, templates, and governance documents in one place.
References
- Schwarzer S, Radzieta M, Jensen SO, Malone M. Efficacy of a Topical Wound Agent Methanesulfonic Acid and Dimethylsulfoxide on In Vitro Biofilms. Int J Mol Sci. 2021;22(17):9471.
- Guest JF, Deanesi V, Segalla A. Cost-effectiveness of DEBRICHEM® in managing hard-to-heal VLUs in the UK. J Wound Care. 2022;31(6).
- Güven HE, Garcia LT, Serena T. The Use of a Novel Desiccating Agent as an Adjuvant Therapy to Surgical Debridement in the Infected Diabetic Foot: A Case Series. 2024.
- Cogo A, Bignozzi C, Hermans MHE, Quint BJ, Snels HP, Schultz G. Case series: 54 patients with multiple aetiologies. J Wound Care. 2022.
- Hermans MHE. Combining an acidic compound and NPWT: debridement and granulation in leg and foot ulcers. 2022.
- Snels HP, Cogo A, Reitano R, et al. Early clinical experience with DEBRICHEM® for wound bed preparation in diabetic foot ulcers. 2025.
- Shabes P, Garabet W, Tilhein S, et al. Pain perception and management during chemical debridement with DEBRICHEM®. 2025.
- Tettelbach WH, et al. Innovative treatment of diabetic ulcers combining chemical debridement and xenograft applications. J Wound Care. 2025.
- Bhatt P, Sharpe A, Staines K, et al. DEBRICHEM® Best Practice Document. J Wound Care. 2024.
- Mayer D, Tettelbach WH, et al. International Consensus Document on Best Practice for Wound Debridement. J Wound Care. 2024.
SCHEDULE YOUR FREE
DEBRICHEM® DEMONSTRATION
The demonstration is completely free, and your patients will receive immediate treatment. We respect your time and privacy. Your information will only be used to schedule your demonstration.
